10-K: Genvor Reports FY25 Loss, Advances AI Peptide Tech

Genvor Incorporated, a pioneer in AI-accelerated peptide technology for sustainable agriculture, reported a significant net loss for fiscal year 2025 while advancing its proprietary BioCypher Algorithm and securing a Bayer Golden Ticket award.

Summary

• Genvor Inc. is focused on AI-accelerated peptide technology for sustainable agriculture, targeting an estimated $220 billion in annual global crop losses.
• The company's proprietary BioCypher Algorithm and extensive library of over 50,000 designed peptides are used to develop Antimicrobial Peptides (AMPs), Nutritionally Enhanced Peptides (NEPs), and Crop-Enhancing Peptides (CEPs).
• Genvor operates a capital-light, licensing-first commercialization model through strategic partnerships, leveraging partners' regulatory expertise and distribution capabilities.
• Reported a net loss of $5,589,041 for the year ended September 30, 2025, which is a 93.7% increase from the $2,884,958 net loss in the prior fiscal year.
• The company had a working capital deficit of $1,312,382 and a cash balance of $37,231 at September 30, 2025, which is insufficient to cover operating expenses for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Genvor was awarded Bayer's Golden Ticket in 2024, providing fully funded access to laboratory space, equipment, and expert mentorship at Bayer's LifeHub California @AgStart.
• The BioCypher algorithm was enhanced by integrating over 9,000 proprietary synthetic AMPs, demonstrating an 85% improvement in training performance.
• Lead peptide candidate GV185 showed strong broad-spectrum antifungal activity at low concentrations against major agricultural pathogens.
• Significant technical formulation advancements were achieved for liquid aqueous formulations of GV185 and GV197, with promising early long-term stability results.
• The company successfully settled legal claims against Justin Kimbrough and Richard Saied, resulting in the cancellation of 331,250 shares and an order for the return of contested shares, respectively.
• Material weaknesses in internal control over financial reporting were identified, including a lack of independent director oversight, a non-functioning audit committee, insufficient accounting personnel, and inadequate written policies.

Sentiment

Score: 3

Explanation: While Genvor shows promising scientific advancements and strategic partnerships (Bayer Golden Ticket, USDA CRADA), its severe financial distress, recurring and increasing losses, lack of revenue, and significant going concern doubt overshadow these positives. The material weaknesses in internal controls and the penny stock status further contribute to a negative sentiment, indicating high risk and an uncertain path to commercial viability.

Positives

• AI-accelerated peptide technology platform (BioCypher Algorithm) shows 85% improvement in training performance after integrating over 9,000 proprietary synthetic antimicrobial peptides.
• Extensive library of more than 50,000 designed peptides addressing high-value agricultural applications, including biological crop protection, yield enhancement, nutrient optimization, and animal health.
• Lead peptide candidate GV185 demonstrated particularly strong broad-spectrum antifungal activity at low concentrations against economically significant pathogens like Fusarium graminearum, Aspergillus flavus, and Botrytis cinerea.
• Achieved significant technical formulation advancements for its antimicrobial peptide (AMP) platform, successfully developing and validating liquid aqueous formulations for GV185 and GV197 for foliar application.
• Awarded Bayer's Golden Ticket in 2024, granting fully funded access to laboratory space, equipment, and expert mentorship at Bayer's LifeHub California @AgStart.
• USDA trials showed transgenic corn peptide AGM182 demonstrated a 72% reduction in fungal growth and a 98% reduction in aflatoxin contamination.
• Secured 5 issued U.S. patents, 2 pending U.S. patent applications, and 4 additional applications in preparation, along with 3 international patent applications, protecting its technology until 2031-2038.
• Favorable court judgments in legal proceedings against Justin Kimbrough and Richard Saied, leading to the return and cancellation of 331,250 shares and an order for the return of contested shares, respectively.
• Working capital deficit decreased by $415,650 to $1,312,382 at September 30, 2025, from $1,728,032 at September 30, 2024.
• Cash balance increased to $37,231 at September 30, 2025, from $373 at September 30, 2024.

Negatives

• Reported a net loss of $5,589,041 for the year ended September 30, 2025, representing a 93.7% increase from the $2,884,958 net loss in the prior fiscal year.
• Operating expenses increased by $3,626,804, or 130.3%, to $6,409,851 for the year ended September 30, 2025.
• Compensation and related benefits increased significantly by $4,180,712, or 317.4%, to $5,497,998 in FY2025, primarily due to stock-based compensation and increased CEO salary and guaranteed bonus.
• The company generated no revenues during the years ended September 30, 2025, and 2024.
• Maintained a working capital deficit of $1,312,382 at September 30, 2025.
• The cash balance of $37,231 at September 30, 2025, is insufficient to cover operating expenses for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• Advertising and marketing expenses decreased by 94.7% due to a lack of capital.
• A Paycheck Protection Program (PPP) loan of $48,750, which matured in April 2022, is currently in default.
• Identified material weaknesses in internal control over financial reporting, including a lack of oversight by independent directors, a non-functioning audit committee, insufficient accounting personnel, and insufficient written policies and procedures.
• The company's common stock is considered 'penny stock' under SEC rules, which may reduce trading activity in the secondary market.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to recurring losses from operations, a net capital deficiency, and the absence of revenues.
• The Company's ability to raise additional capital through debt or future issuances of capital stock is uncertain, and there is no assurance that such financing will be available on satisfactory terms or at all.
• The future sale of presently outstanding unregistered and restricted common stock by present members of management and persons owning more than five percent of the Company's voting securities may have an adverse effect on any established trading market.
• There is no assurance that the Company's pending patent applications will result in issued patents, that any issued patents will provide adequate protection for its technology, or that third parties will not assert intellectual property infringement claims.
• The Company remains exposed to the risk of cybersecurity threats, and while measures are in place, there is no guarantee against material effects on business strategy, results of operations, or financial condition.
• Regulatory changes that impose additional restrictions or requirements on the Company or its products could adversely affect operations by increasing costs or decreasing demand.
• Potential conflicts of interest exist as directors and officers have the authority to determine issues concerning management compensation, nominations, and audit matters.
• The impact of tariffs and changes to global trade policies on the Company's results of operations is uncertain.

Future Outlook

The Company expects research and development expenses to continue increasing as it works towards commercializing its products. Advertising and marketing expenses are projected to remain at current minimal levels due to capital constraints. Genvor does not anticipate generating revenue until the end of 2025, primarily through licensing and distribution of its topical spray and seed traits. The Company plans to raise additional capital through debt and/or equity financing arrangements to fund ongoing operations, R&D activities, and potential internal infrastructure development, such as a dedicated laboratory facility near Sacramento, California.

Management Comments

• Our outreach efforts extended to major agricultural enterprises, facilitating discussions on potential partnership opportunities to bring Genvor’s peptide portfolio to market.
• The company is collaborating with several contract manufacturing firms to develop efficient and cost-effective manufacturing systems.
• Management believes that the actions presently being taken to further implement its business plan, develop its products and technologies, and generate revenues should provide the opportunity for the Company to continue as a going concern.
• Management provides no assurances that it will be able to [obtain additional funding].
• Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s disclosure controls and internal controls will prevent all error and all fraud.

Industry Context

Genvor operates at a critical inflection point in agricultural innovation, where converging factors such as climate change impacts, evolving pest resistance, tightening regulations, and consumer preferences are driving unprecedented demand for sustainable agricultural solutions. The global agricultural biologicals market, valued at approximately $9.5 billion in 2019, is projected to grow to $19.7 billion by 2026, indicating a strong market tailwind for Genvor's peptide-based solutions. The company's focus on residue-free, biodegradable products aligns well with global regulatory trends restricting chemical pesticide usage and increasing consumer demand for sustainably produced food.

Comparison to Industry Standards

• Genvor's AI-accelerated discovery capabilities through the BioCypher Algorithm enable rapid iteration and optimization of peptide candidates, dramatically reducing time-to-market compared to traditional agricultural R&D cycles.
• The company's peptide-based solutions qualify for expedited regulatory pathways as biological products, which typically reduce approval timelines and costs compared to synthetic chemical alternatives.
• Peptides' multiple modes of action and biodegradability minimize resistance development risks, a significant challenge for conventional chemical pesticides.
• The value of Genvor's Cooperative Research and Development Agreement (CRADA) with the USDA is highlighted, allowing the company to bring seed traits to market with substantially less capital investment (under $700,000 contribution) compared to the industry average of eight years and $136 million.
• Competitors in the peptide-based crop protection market include Vestaron Corporation (offering EPA-registered insecticides like Spear T and Spear RC), BASF SE (incorporating peptide-enhanced products like Inscalis), Syngenta Crop Protection (advancing peptides for fungal disease control), Micropep Technologies (pioneering micropeptide solutions with over $51 million in funding), and Hello Nature (providing plant-stimulating peptides as biostimulants).

Management Changes

Corporate Governance

Legal Proceedings

• Company filed suit against Justin Kimbrough and Prosperity Consultants, LLC, alleging fraud and conversion. The claims were settled, requiring Mr. Kimbrough to return 331,250 shares of common stock, which were cancelled on October 22, 2025.
• Company filed suit against Richard Saied, alleging fraud and conversion for improper receipt of shares. On October 29, 2025, the court entered judgment in the Company's favor, awarding reasonable and necessary attorney fees and ordering Mr. Saied to return the contested shares.
• Judith Miller sent a letter to the Company on October 13, 2024, demanding payment for amounts she claimed were owed under her prior employment agreement; the Company disputes these allegations and intends to defend itself.

Related Party Transactions

• Accrued compensation and related expenses owed to CEO Chad Pawlak and scientific advisors Dr. Jesse Jaynes and Dr. Clayton Yates totaled $742,488 at September 30, 2025, up from $466,404 in FY2024.
• The CEO and scientific advisors make working capital advances to the Company, bearing 8% interest. Advances from related parties totaled $84,137 at September 30, 2025, up from $17,062 in FY2024.
• Accrued interest due to the CEO and scientific advisors was $54,814 at September 30, 2025, up from $9,705 in FY2024.
• The Company owed its former chief business officer and interim chief financial officer, Judith Miller, $38,904 primarily from accrued compensation as of September 30, 2025.
• In May 2025, the Company settled a $217,000 debt owed to Brent Lilienthal (a noteholder) by issuing 120,000 shares of common stock.
• The Company executed a release and settlement agreement with former CEO Bradley White on June 11, 2025, agreeing to pay $55,000 for all outstanding amounts.
• In May 2025, the CEO converted $125,000 of accrued compensation into 500,000 shares of common stock, and scientific advisors converted $200,000 of accrued bonuses into 800,000 shares of common stock.
• On December 1, 2025, Dr. Jesse Jaynes converted $186,000 of outstanding liabilities (accrued salary, accrued interest, and working capital advances) into 124,000 shares of common stock.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity raises, as well as conversions of debt and compensation into common stock. The 'penny stock' status and lack of an established trading market pose liquidity challenges. The substantial net losses and going concern doubt indicate high investment risk.
• Employees, particularly the CEO and scientific advisors, have a significant portion of their compensation tied to stock-based awards, aligning their financial interests with the company's stock performance. Scientific advisors have seen increased monthly compensation and milestone-based bonuses.
• Future customers stand to benefit from potentially more sustainable and effective crop protection solutions, which could reduce crop losses and align with the growing demand for residue-free agricultural products.
• Creditors face elevated risk due to the company's going concern status and recurring losses. The PPP loan is in default, though other notes payable have been settled or derecognized.
• Regulatory bodies are engaged through the USDA CRADA and anticipated EPA/FDA approvals, indicating the company's efforts to comply with agricultural and environmental standards.

Next Steps

• Continue research and development projects, particularly for commercializing products.
• Continue stability studies for lead peptide prototypes (GV185 and GV197) and proceed with efficacy testing in controlled greenhouse and field environments.
• Pursue regulatory pathways and strategic collaborations to advance the development and commercialization of its peptide technologies for both domestic and international markets.
• Expect an extension of the USDA CRADA to continue studies of Genvor's 4th generation of peptides (GNV-185 and GNV-187) towards commercialization.
• Plan to apply for additional CRADAs with the USDA for nutritionally enhanced peptides (NEPs) in poultry and swine feed, and for aflatoxins in peanuts.
• Actively evaluate various financing options and seek additional capital through debt and/or equity financing arrangements.
• Assess the potential establishment of a dedicated laboratory facility in or near Sacramento, California, to support internal R&D and pilot-scale development.
• Implement measures to remediate internal control weaknesses, including adding a sufficient number of independent directors to the board, appointing an audit committee, hiring sufficient knowledgeable accounting personnel, and developing adequate written accounting policies and procedures.
• Review and establish appropriate Board-level oversight for cybersecurity and evaluate options to enhance management's cybersecurity role through additional training or external expertise.
• Adopt a written code of ethics in the near future.

Key Dates

Recommendation

Genvor Incorporated presents an extremely high-risk investment profile. The company has a history of recurring and significantly increasing net losses, with no revenue generated in the reported fiscal years. The current cash balance is critically low ($37,231) and insufficient to cover operations for the next 12 months, leading to substantial doubt about its ability to continue as a going concern. While the company's AI-accelerated peptide technology and strategic partnerships (Bayer Golden Ticket, USDA CRADA) show scientific promise, the path to commercialization and profitability is highly uncertain and capital-intensive. The identified material weaknesses in internal controls and the 'penny stock' designation further exacerbate the risk. Investors face significant dilution risk from ongoing capital raises and conversions of liabilities into equity. Given the severe financial distress, lack of revenue, and significant operational and governance challenges, a seasoned investor would strongly recommend selling any existing positions and avoiding new investments.

Keywords

AI-accelerated peptide technology, sustainable agriculture, crop protection, antimicrobial peptides, BioCypher Algorithm, plant diseases, aflatoxin, USDA CRADA, biopesticides, seed traits, animal health, biotechnology, agricultural innovation, Genvor, SEC 10-K